Sam Altman and his husband have reportedly invested in a gene-editing startup focused on eliminating hereditary diseases, as per a news headline dated November 14, 2025. This indicates a potential future growth area in biotechnology and gene-editing firms. Investors interested in long-term, high-impact ventures might consider researching private or publicly traded companies in this nascent field.